Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes Peggs KS, Sureda A, Qian W, Caballero D, Hunter A, Urbano-Ispizua A, Cavet J, Ribera JM, Parker A, Canales M, Mahendra P, Garcia-Conde J, Milligan D, Sanz G Thomson K, Arranz R, Goldstone AH, Alvarez I, Linch DC, Sierra J, Mackinnon S. On behalf of the UK and Spanish Collaborative Groups. British Journal of Haematology 139(1):70-80. FI: 4.597 (Q1) Primary mediastinal large cell lymphoma(PMBL): frontline treatment with autologous stem cell transplantation(ASCT)The GEL-TAMO experience Rodríguez J, Conde E, Gutiérrez A, García JC, Lahuerta JJ, Varela MR, Pérez C, Albo C, Caballero D. Hematological Oncology 26(3):171-8. FI: 1.869 (Q3) High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation Kyriakou C, Canals C, Goldstone A, Caballero D, Metzner B, Kobbe G, Kolb HJ, Kienast J, Reimer P, FInke J, Oberg G, Hunter A, Theorin N, Sureda A, Schmitz N, Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology 26(2):218-24. FI: 17.793 (Q1) R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, Andreu R, Salar A, García-Sanchez P, Vázquez L, Nistal S, Requena MJ, Donato EM, González JA, León A, Ruiz C, Grande C, González-Barca E, Caballero D, on behalf of the Grupo Español de Linfomas/Trasplante Autólogo de Médula Ósea (GEL/TAMO cooperative group). Haematologica 93(12):1829-36. FI: 6.416 (Q1) Correlation between prepulse inhibition and cortical perfusion during an attentional test in schizophrenia. A pilot study Molina V, Montes C, Tamayo P, Villa R, Osuna MI, Pérez J, Sancho C, López-Albuquerque T, Cardoso A, Castellano O, López DE. Progress in Neuropsychopharmacology and Biological Psychiatry 33(1):53-61. FI: 2.823 (Q2) Treatment with bortezomib of human CD4. T cells preserves natural regulatory T cells and allows the emergence of a distinct suppressor T-cell population Blanco B, Pérez-Simón JA, Sánchez-Abarca LI, Caballero-Velázquez T, Gutiérrez-Cossío S, Hernández-Campo P, Díez-Campelo M, Herrero-Sánchez C, Rodríguez-Serrano C, Santamaría C, Sánchez-Guijo FM, Del Cañizo C,San Miguel JF. Haematologica 94(7):975-83. FI: 6.416 (Q1) Identification of biological markers of sensitivity to high-clinical-risk-adapted therapy for patients with diffuse large B-cell lymphoma Sáez AI, García-Cosío M, Sáez AJ, Hernández JM, Sánchez-Verde L, Álvarez D, de la Cueva P, Arranz R, Conde E, Grande C, Rodríguez J, Caballero D, Piris MA. Leukemia & Lymphoma 50(4):571-81. FI: 2.397 (Q3) Liver function tests and absolute lymphocyte count at day . 100 are predictive factors for extensive and severe chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplant Silva F, Pérez-Simón JA, Caballero Velázquez T, Encinas C, Sánchez-Guijo FM, Díez-Campelo M, Colado E, Martín J, Villanueva-Gómez F, Vázquez L, Del Cañizo C, Caballero D, San Miguel JF. American Journal of Hematology 85(4):290-3. FI: 2.610 (Q2) Recommendations for the use of serum free light chains assay in plasma cell disorders L. López-Corral, R. García-Sanz, J.F San Miguel. Medicina Clínica 11:135(8):368-74. FI: 1.410 (Q2) Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura Pérez-Simón JA, Tabera S, Sarasquete ME, Díez-Campelo M, Canchado J, Sánchez-Abarca LI, Blanco B, Alberca I, Herrero-Sánchez C, Cañizo C, San Miguel JF. Cytotherapy FI: 2.204 (Q2)
|
